Dermatology drugmaker Biofrontera's Q4 revenue rises to record high on Ameluz strength

Biofrontera

19/03/2026 13:36

((This story was generated using AI and automation, please see
disclaimer https://bit.ly/rtrsnai))
    
    Overview
  
    * US biopharma firm's Q4 revenue rose 36% yr/yr to record high, driven by Ameluz sales
    * Company posted Q4 net income of $5.6 mln, reversing prior-year loss
    * Gross margin improved to 82.4% in Q4, reflecting lower costs after strategic transaction

    
    Outlook
  
    * Company expects full annualized benefits of new cost structure to be realized in 2026
    * Biofrontera anticipates shift toward sustained profitability and cash flow breakeven in 2026

    
    Result Drivers
  
    * AMELUZ SALES EXECUTION - Co said record Q4 revenue growth was primarily driven by strong Ameluz sales execution and pricing adjustment
    * COST STRUCTURE TRANSFORMATION - Transition to lower earnout structure after strategic transaction with Biofrontera AG materially reduced cost of goods sold
    * LEGAL EXPENSES - Higher legal costs increased operating expenses in Q4

    
Company press release:  ID:nGNXbdZf78 
    
    Key Details
  
                               
                               
 Metric    Beat/Mis  Actual    Consensu
           s                   s
                               Estimate
                               
                               
 Q4        Beat      $17.10    $16.15
 Revenue             mln       mln (2
                               Analysts
                               )
 Q4 Net              $5.60      
 Income              mln       
 Q4                  $4.90      
 Adjusted            mln       
 EBITDA                        
 Q4                  $12.50     
 Operatin            mln       
 g                             
 Expenses                      
    
    Analyst Coverage
  
    * The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
    * The average consensus recommendation for the pharmaceuticals peer group is "buy"
    * Wall Street's median 12-month price target for Biofrontera Inc is $6.00, about 590.8% above its March 18 closing price of $0.87

    
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)